Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAR HMB Pilot Trial in ALS
NCT07589764Phase 1Not yet recruiting
- Sponsor
- Duke University
- Start
- Dec 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of β-hydroxy-β-methylbutyric acid in amyotrophic lateral sclerosis (ALS), sponsored by Duke University. Primary endpoints: ALS Functional Rating Scale, Revised at 9 months and Speech (Listener Effort) at 9 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
β-hydroxy-β-methylbutyric acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07589764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589764.